ANI Pharmaceuticals reports stronger-than-expected Q2 results, driven by 43.5% growth in Cortrophin Gel sales.
ANI Pharmaceuticals posted Q2 non-GAAP EPS of $2.21, exceeding estimates by $0.17, as revenue rose 25.8% year-over-year to $266.04 million. The beat included a $5.91 million revenue upside, supported by Purified Cortrophin Gel net sales of $117.1 million, up 43.5% from the prior year.
The company reaffirmed its full-year 2026 total net revenue guidance, signaling confidence in sustained growth. Prior-year Q2 revenue was not provided for direct comparison, but the 25.8% annual increase highlights strong demand for its key products.
No immediate market reaction was disclosed in the release.